A dirt-cheap FTSE 100 dividend stock I’d buy for my ISA and hold until 2029

Attention FTSE 100 investors! This is a dividend stock worth buying now and holding for the next 10 years, says Royston Wild.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A FTSE 100 stock I reckon is a great pick for novice share pickers and experienced equity investors alike is The Berkeley Group (LSE: BKG).

I’m not going to pretend that everything is fine and dandy over at the blue-chip housebuilder. Brexit fears continue to crimp buyer activity in its core markets of London and the South East, geographies where property prices have long been accused of being severely overheated. Current political and economic uncertainty means that homebuyers are thinking twice before taking the plunge, but I believe this will end up being a short-lived phenomenon.

London calling

Make no mistake: these regions in the south of England are the engine room of the UK economy, and in the case of London, a market that has been popular with both residential owners and investors for centuries. Once the current political deadlock around Brexit is broken I expect buying activity to pick up at Berkeley, and fast.

Besides, it’s not as if business conditions at Berkeley are sinking at an alarming rate. In its most recent trading statement of 6 September the construction colossus advised that “market conditions in London and the South East have remained robust” in the first four months of the current financial year, the business adding that “pricing has remained stable and the group’s forward sales position remains above £1.8bn.”

City analysts, then, expect the builder to return to earnings growth in the next financial year with a 2% bottom-line advance. Decent dividend yields of 3.8% and 4% for the fiscal periods to April 2020 and 2021 provide plenty to get excited about, too. And a low forward price-to-earnings ratio of 14.1 times, despite its recent ascent to record highs around £47.80, gives long-term investors an attractive entry point to buy in.

The right medicine

Before you go I’d like to shine a light on AstraZeneca (LSE: AZN), another brilliant Footsie share with the wind in its sails right now. Its share price has recently crept back towards the record closing highs of £75.80 of late October, and despite its elevated forward P/E ratio of 27 times I expect it to hit new peaks sooner rather than later.

In my book pharmaceuticals star AstraZeneca is every inch a stock worthy of a hefty premium to the broader FTSE 100 (where the broader forward average sits closer to 15 times). I recently celebrated the strength of the company’s pipeline of new treatments and newsflow since then has reinforced my enthusiasm.

A string of positive testing and regulatory updates in recent weeks includes the approval of its Qtrilmet diabetes battler in Europe, and US lawmakers granting fast-track review status for its selumetinib drug for the treatment of neurofibromatosis type 1 in children. AstraZeneca’s new product lineup is already lighting a fire under the bottom line, causing City analysts to predict that the 4% earnings rise for 2019 will improve to 19% next year. And this recent news gives commentators more reason to be cheery about the business for well into the next decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »